{"disease":{"id":"indication-under-phase-1-evaluation-not-specified","name":"indication under phase 1 evaluation not specified"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odm-108-part-iii","indication_name":"Indication under Phase 1 evaluation (not specified)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODM-108 Part III","company_name":"Orion Corporation, Orion Pharma","drug_phase":"discontinued","molecular_target":"Not publicly disclosed","drug_class":"Unknown — investigational small molecule","quality_score":null,"revenue":null,"mechanism":"ODM-108 mechanism of action is not publicly disclosed; Phase 1 evaluation focused on safety and pharmacokinetics in healthy volunteers."},{"drug_id":"odm-108-part-i","indication_name":"Indication under Phase 1 evaluation (not specified)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODM-108 Part I","company_name":"Orion Corporation, Orion Pharma","drug_phase":"discontinued","molecular_target":"Not disclosed","drug_class":"Small molecule (investigational)","quality_score":null,"revenue":null,"mechanism":"ODM-108 Part I mechanism of action is not publicly disclosed; Phase 1 development was terminated."}],"offLabel":[],"totalMarketed":0,"totalPipeline":2},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}